European Biotech Acquisition Corp
Change company Symbol lookup
Select an option...
EBACU European Biotech Acquisition Corp
$SMOVE3M ICE BofAML Swap MOVE 3-Month Index
FSMAX Fidelity® Extended Market Index Fund
PFE Pfizer Inc
DUNE Dune Acquisition Corp
METV Roundhill Ball Metaverse ETF
TBNK Territorial Bancorp Inc
BAC Bank of America Corp
ICD Independence Contract Drilling Inc

Based in Netherlands
Company profile

European Biotech Acquisition Corp is a blanc check company based in the Netherlands. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The Company intends to primarily seek to identify a company within the European life sciences industry. The aim of the Company is investments in therapeutic drug candidates in clinical development across a range of therapeutic areas, including oncology, diabetes, cardiology, central nervous system (CNS) and orphan diseases.

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low

10-day average volume:

Tilray expected to grow sales sequentially but remain in the red

1:01 pm ET January 6, 2022 (MarketWatch)

By Steve Gelsi

Tilray grows its top line even as it faces a potential loss in the quarter

Tilray Inc. will likely grow its sales over the previous quarter but it's expected to post a net loss when it becomes the first major cannabis company to post quarterly results in 2022 on Monday.

Tilray TLRYCA:TLRY is expected to post a second-quarter loss of 8 cents a share, flat with the loss of 8 cents a share posted in the previous quarter, according to an analyst survey by FactSet.

Tilray's results will be followed by updates in coming weeks from other Canadian companies such as Canopy Growth Corp. (WEED.T), Cronos Group (CRON.T) and Aurora Cannabis (ACB.T); as well as U.S. companies such as Curaleaf , Trulieve Cannabis Corp. and Green Thumb Industries .

Analysts have been growing more bearish on Tilray's prospects in recent months amid price pressure and market share losses to smaller rivals.

Since October, analysts have reduced their outlook for Tilray a total of 20 times, compared to 21 unchanged estimates and six instances of increased estimates, according to FactSet.

Despite the dimmer view on profits, Tilray's sales continue to grow. The company is expected to report $173.7 million in sales for the second quarter, up from $168 million in the first quarter. The first quarter result fell short of Wall Street's $172.6 million estimate.

See Also:Tilray shares climb as investors shrug off revenue miss and bigger-than-expected loss

Year-ago figures are not comparable for Tilray, given the impact of its acquisition of Aphria, which closed in May 2021.

Alliance Global Partners analyst Aaron Grey said Tuesday that Tilray and other Canadian producers benefitted from a 7.8% growth over the previous month to C$369 million. Industrywide sales increased by 32% over the year-ago figure.

"Pricing pressure in the marketplace continued as every product category with the exception of beverages and oil," Grey said

Tilray, which continues to be the market share leader in Canada, lost 115 basis points of market share to 10.8%.

Amid analyst moves in recent weeks on Tilray, Bill Kirk of MKM Partners on Dec. 10 cut his fair value price target on Tilray to $10 a share from $16 and reiterated a neutral rating on the company.

Canopy Growth (WEED.T), the unit of Constellation Brands (STZ) that operates in the Canadian market, lost about 100 basis points in market share.

All told, the top five Canadian cannabis companies led by Tilray held 43.9% market share in December compared to 46% in November. Top five player OrganiGram Holdings OGI marked the only exception among the bigger players by increasing its market share by 35 basis points to 7.6%.

Canadian companies outside the top five increased their market share by a combined 210 basis points. Among those, Village Farms (VFF) gained 35 basis points of market share to a total of 6.4%.

Overall, shares of Tilray and other cannabis companies have been weak given the oversupply dynamics in the Canadian market, combined with a reduction in some economic activity due to COVID-19.

The Cannabis ETF (THCX) is now trading at about $8.19, down from about $12.50 three months ago. The index has been impacted by a lack of action on legalization on the federal front in the U.S., even as several large states such as New York and Illinois continue to scale up their legal cannabis business.

For its part, Tilray shares have sunk to below $7 a share after trading at about $11 three months ago.

See Also:Investors in cannabis companies burned by stock-market losses in 2021 even as the pot business grows

-Steve Gelsi


(END) Dow Jones Newswires

January 06, 2022 13:01 ET (18:01 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.